Resistance to the Platinum‑based Chemotherapeutic Drugs in Oral Cancer: Focus on the Role of P22phox (Review)

Overview

Journal Biomed Rep

Specialty Biochemistry

Date 2024 Oct 18

PMID 39420922

Authors

Jin-Ching Lee

Ching-Ying Wu

Tsai-Hui Duh

Tai-Jan Chiu

Chien-Chih Chiu

Chiu-Hsien Lee

Jeff Yi-Fu Chen

Affiliations

Soon will be listed here.

Abstract

Oral cancer, commonly known as oral squamous cell carcinoma (OSCC), is an aggressive malignancy in the oral cavity with a poor prognosis and survival rate, particularly at the advanced stages. Oral cancer represents one of the most widespread cancers worldwide, in which the prevalence is particularly high in South and Southeast Asia. While the incidence and mortality rates continue to increase over the past decades, oral cancer treatment can be challenging and at times ineffective, largely due to drug resistance. To date, platinum-based drugs, such as cisplatin, remain the mainstay of chemotherapy for patients with oral cancer. However, long-term exposure to cisplatin inevitably leads to the development of resistance to the drug, which is still a major issue to overcome in oral cancer treatment. The molecular mechanisms of cisplatin resistance in oral cancer have been extensively studied in recent years and the present review places specific emphasis on a novel mechanism of resistance to the platinum drugs mediated by p22phox, an endoplasmic reticulum membrane protein. In addition to delineating the unique p22phox-dependent cisplatin resistance, the present review compares and contrasts the resistance mechanism to its current counterparts. Finally, with the goal of tackling the problem of chemotherapy resistance in oral cancer, various strategies are presented that may counteract p22phox-dependent cisplatin resistance, which may potentially improve the efficacy of the platinum-based drugs and warrant future clinical validation.

References

Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, Lage H . Augmented expression of metallothionein and glutathione S-transferase pi as unfavourable prognostic factors in cisplatin-treated ovarian cancer patients. Virchows Arch. 2005; 447(3):626-33. DOI: 10.1007/s00428-005-1228-0. View

Hishikawa Y, Abe S, Kinugasa S, Yoshimura H, Monden N, Igarashi M . Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology. 1997; 54(4):342-7. DOI: 10.1159/000227714. View

Hyodo T, Kuribayashi N, Fukumoto C, Komiyama Y, Shiraishi R, Kamimura R . The mutational spectrum in whole exon of p53 in oral squamous cell carcinoma and its clinical implications. Sci Rep. 2022; 12(1):21695. PMC: 9755123. DOI: 10.1038/s41598-022-25744-8. View

Kelley S, Basu A, Teicher B, Hacker M, Hamer D, Lazo J . Overexpression of metallothionein confers resistance to anticancer drugs. Science. 1988; 241(4874):1813-5. DOI: 10.1126/science.3175622. View

Zhao H, Piwnica-Worms H . ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol. 2001; 21(13):4129-39. PMC: 87074. DOI: 10.1128/MCB.21.13.4129-4139.2001. View

Guha N, Warnakulasuriya S, Vlaanderen J, Straif K . Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for cancer control. Int J Cancer. 2013; 135(6):1433-43. DOI: 10.1002/ijc.28643. View

Martyn K, Frederick L, von Loehneysen K, Dinauer M, Knaus U . Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal. 2005; 18(1):69-82. DOI: 10.1016/j.cellsig.2005.03.023. View

Kobayashi M, Saito R, Miki Y, Nanamiya R, Inoue C, Abe J . The correlation of p22 and chemosensitivity in EGFR-TKI resistant lung adenocarcinoma. Oncotarget. 2019; 10(10):1119-1131. PMC: 6383684. DOI: 10.18632/oncotarget.26637. View

Liu C, Wang M, Zhang H, Li C, Zhang T, Liu H . Tumor microenvironment and immunotherapy of oral cancer. Eur J Med Res. 2022; 27(1):198. PMC: 9547678. DOI: 10.1186/s40001-022-00835-4. View

10.

Karasawa T, Sibrian-Vazquez M, Strongin R, Steyger P . Identification of cisplatin-binding proteins using agarose conjugates of platinum compounds. PLoS One. 2013; 8(6):e66220. PMC: 3670892. DOI: 10.1371/journal.pone.0066220. View

11.

Wu T, Wang M, Jing L, Liu Z, Guo H, Liu Y . Autophagy facilitates lung adenocarcinoma resistance to cisplatin treatment by activation of AMPK/mTOR signaling pathway. Drug Des Devel Ther. 2015; 9:6421-31. PMC: 4686226. DOI: 10.2147/DDDT.S95606. View

12.

Hsu D, Lan H, Huang C, Tai S, Chang S, Tsai T . Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer. Clin Cancer Res. 2010; 16(18):4561-71. DOI: 10.1158/1078-0432.CCR-10-0593. View

13.

Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T . The involvement of hypoxia-inducible factor-1alpha in the susceptibility to gamma-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int J Cancer. 2006; 120(2):268-77. DOI: 10.1002/ijc.22294. View

14.

Moltgen S, Piumatti E, Massafra G, Metzger S, Jaehde U, Kalayda G . Cisplatin Protein Binding Partners and Their Relevance for Platinum Drug Sensitivity. Cells. 2020; 9(6). PMC: 7349790. DOI: 10.3390/cells9061322. View

15.

Branch P, Masson M, Aquilina G, Bignami M, Karran P . Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells. Oncogene. 2000; 19(28):3138-45. DOI: 10.1038/sj.onc.1203668. View

16.

Block K, Gorin Y, New D, Eid A, Chelmicki T, Reed A . The NADPH oxidase subunit p22phox inhibits the function of the tumor suppressor protein tuberin. Am J Pathol. 2010; 176(5):2447-55. PMC: 2861109. DOI: 10.2353/ajpath.2010.090606. View

17.

Liu T, Chen G, Sun D, Lei M, Li Y, Zhou C . Exosomes containing miR-21 transfer the characteristic of cisplatin resistance by targeting PTEN and PDCD4 in oral squamous cell carcinoma. Acta Biochim Biophys Sin (Shanghai). 2017; 49(9):808-816. DOI: 10.1093/abbs/gmx078. View

18.

Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M . Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst. 2009; 101(1):37-47. PMC: 2639295. DOI: 10.1093/jnci/djn418. View

19.

Alcindor T, Beauger N . Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol. 2011; 18(1):18-25. PMC: 3031353. DOI: 10.3747/co.v18i1.708. View

20.

Tian H, Gao Z, Li H, Zhang B, Wang G, Zhang Q . DNA damage response--a double-edged sword in cancer prevention and cancer therapy. Cancer Lett. 2014; 358(1):8-16. DOI: 10.1016/j.canlet.2014.12.038. View